By: Representative Hobgood-Wilkes

To: Drug Policy; Business and Commerce

HOUSE BILL NO. 1121

- 1 AN ACT TO AMEND SECTION 41-29-117, MISSISSIPPI CODE OF 1972, TO ADD KRATOM TO SCHEDULE III OF THE UNIFORM CONTROLLED SUBSTANCES 2 3 ACT; AND FOR RELATED PURPOSES.
- BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI: 4
- **SECTION 1.** Section 41-29-117, Mississippi Code of 1972, is 5
- amended as follows: 6
- 7 41-29-117. (A) The controlled substances listed in this
- section are included in Schedule III. 8
- 9 SCHEDULE III
- 10 Stimulants. Any material, compound, mixture, or
- 11 preparation which contains any quantity of the following
- 12 substances or their salts, isomers, or salts of isomers, of the
- 13 following substances:
- 14 (1)Benzphetamine;
- 15 (2) Chlorphentermine;
- 16 (3) Clortermine;
- 17 (4) Phendimetrazine.

H. B. No. 1121

18	(b) Depressants. Unless listed in another schedule,											
19	any material, compound, mixture, or preparation which contains any											
20	quantity of the following substances:											
21	(1) Any substance which contains any quantity of a											
22	derivative of barbituric acid, or any salt of a derivative of											
23	barbituric acid, except those substances which are specifically											
24	listed in other schedules;											
25	(2) Unless specifically excepted or unless listed											
26	in another schedule, any compound, mixture or preparation											
27	containing any of the following substances or any salt of the											
28	substances specifically included in this subsection (2) and one or											
29	more other active medicinal ingredients which are not listed in											
30	any other schedule:											
31	(i) Amobarbital;											
32	(ii) Secobarbital;											
33	(iii) Pentobarbital;											
34	(3) Any suppository dosage form containing any of											
35	the following substances or any salt of any of the substances											
36	specifically included in this subsection (3) approved by the Food											
37	and Drug Administration for marketing only as a suppository:											
38	(i) Amobarbital;											
39	(ii) Secobarbital;											
40	(iii) Pentobarbital;											
41	(4) Chlorhexadol;											
12	(5) Embutramide;											

18

```
43
                        Any drug product containing
    gamma-hydroxybutyric acid, including its salts, isomers and salts
44
    of isomers, for which an application is approved under Section 505
45
    of the Federal Food, Drug and Cosmetic Act;
46
47
                        Ketamine; its salts, isomers, and salts of
48
    isomers; other names include
    (+)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone;
49
50
                    (8)
                        Lysergic acid;
51
                        Lysergic acid amide;
                    (9)
52
                    (10) Methyprylon;
53
                    (11)
                          Perampanel; its salts, isomers, and salts of
54
    isomers;
55
                    (12)
                          Sulfondiethylmethane;
56
                          Sulfonethylmethane;
                    (13)
57
                    (14)
                          Sulfonmethane;
58
                    (15)
                          Tiletamine and zolazepam or any salt thereof;
59
    other names for the tiletamine and zolazepam combination product
    include: telazol; other names for tiletamine include:
60
61
    2-(ethylamino)-2-(2-thienyl)-cyclohexanone; other names for
62
    zolazepam include: 4-(2-fluorophenyl)-6,8-dihydro 1,3,
    8-trimethylpyrazolo-[3,4-e](1,4)-diazepin-7(1H)-one, flupyrazapon.
63
64
               (C)
                    Nalorphine.
65
               (d)
                    Any material, compound, mixture or preparation
66
    which contains any quantity of ephedrine or pseudoephedrine,
    except for any product that contains any quantity of
67
```

H. B. No. 1121

- 68 pseudoephedrine or ephedrine that is sold subject to the quantity
- 69 restrictions authorized in Section 73-21-124.
- 70 (e) Narcotic drugs. Any material, compound, mixture,
- 71 or preparation containing limited quantities of any of the
- 72 following narcotic drugs, or any salts thereof:
- 73 (1) Not more than one and eight-tenths (1.8) grams
- 74 of codeine, or any of its salts, per one hundred (100) milliliters
- 75 or not more than ninety (90) milligrams per dosage unit, with an
- 76 equal or greater quantity of an isoquinoline alkaloid of opium;
- 77 (2) Not more than one and eight-tenths (1.8) grams
- 78 of codeine, or any of its salts, per one hundred (100) milliliters
- 79 or not more than ninety (90) milligrams per dosage unit, with one
- 80 or more active, nonnarcotic ingredients in recognized therapeutic
- 81 amounts;
- 82 (3) Not more than one and eight-tenths (1.8) grams
- 83 of dihydrocodeine, or any of its salts, per one hundred (100)
- 84 milliliters or not more than ninety (90) milligrams per dosage
- 85 unit, with one or more active, nonnarcotic ingredients in
- 86 recognized therapeutic amounts;
- 87 (4) Not more than three hundred (300) milligrams
- 88 of ethylmorphine, or any of its salts, per one hundred (100)
- 89 milliliters or not more than fifteen (15) milligrams per dosage
- 90 unit, with one or more active, nonnarcotic ingredients in
- 91 recognized therapeutic amounts;

```
92
                     (5)
                         Not more than five hundred (500) milligrams of
 93
     opium per one hundred (100) milliliters or per one hundred (100)
     grams, or not more than twenty-five (25) milligrams per dosage
 94
     unit, with one or more active, nonnarcotic ingredients in
 95
96
     recognized therapeutic amounts;
97
                         Not more than fifty (50) milligrams of
     morphine, or any of its salts, per one hundred (100) milliliters
98
     or per one hundred (100) grams with one or more active,
99
100
     nonnarcotic ingredients in recognized therapeutic amounts.
101
                (f)
                     Anabolic steroids. Unless specifically exempted or
102
     listed in another schedule, any material, compound, mixture or
     preparation containing any quantity of any of the following
103
104
     anabolic steroids (any drug or hormonal substance chemically and
105
     pharmacologically related to testosterone other than estrogens,
     progestins, corticosteroids and dehydroepiandrosterone):
106
107
                     (1)
                          3beta, 17-dihydroxy-5a-androstane;
108
                          3alpha, 17beta-dihydroxy-5a-androstane;
                     (2)
109
                          5alpha-androstan-3,17-dione;
                     (3)
110
                     (4)
                          1-androstenediol
111
     (3beta, 17beta-dihydroxy-5alpha-androst-1-ene);
112
                     (5)
                         1-androstenediol
113
     (3alpha, 17beta-dihydroxy-5alpha-androst-1-ene);
114
                          4-androstenediol
                     (6)
     (3beta, 17beta-dihydroxy-androst-4-ene);
115
```

```
116
                     (7)
                          5-androstenediol
117
     (3beta, 17beta-dihydroxy-androst-5-ene);
118
                     (8)
                          1-androstenedione ([5alpha]-androst-1-en-3,
119
     17-dione);
120
                     (9)
                         4-androstenedione (androst-4-en-3,17-dione);
121
                     (10) 5-androstenedione (androst-5-en-3,17-dione);
122
                     (11) Bolasterone
123
     (7alpha, 17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);
124
                     (12) Boldenone
125
     (17beta-hydroxyandrost-1, 4, -diene-3-one);
126
                     (13)
                           Boldione (androsta-1, 4-diene-3, 17-dione);
127
                     (14) Calusterone
128
     (7beta, 17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);
129
                     (15) Clostebol
     (4-chloro-17beta-hydroxyandrost-4-en-3-one);
130
131
                     (16)
                           Dehydrochloromethyltestosterone
132
     (4-chloro-17beta-hydroxy-17alpha-methylandrost-1,4-dien-3-one);
133
                     (17) Desoxymethyltestosterone
134
     (17alpha-methyl-5alpha-androst-2-en-17beta-ol, also known as
135
     madol);
136
                     (18)
                           Delta1-dihydrotestosterone (also known as
     1-testosterone) (17beta-hydroxy-5alpha-androst-1-en-3-one);
137
138
                     (19)
                           4-dihydrotestosterone
139
     (17beta-hydroxy-androstan-3-one);
```

H. B. No. 1121

25/HR43/R1778 PAGE 6 (RKM\KP)

```
140
                     (20)
                          Drostanolone
141
     (17beta-hydroxy-2alpha-methyl-5alpha-androstan-3-one);
142
                     (21) Ethylestrenol
143
     (17alpha-ethyl-17beta-hydroxyestr-4-ene);
144
                     (22) Fluoxymesterone
145
     (9-fluoro-17alpha-methyl-11beta,
146
     17beta-dihydroxyandrost-4-en-3-one);
147
                     (23)
                          Formebolone
148
     (2-formyl-17alpha-methyl-11alpha, 17beta-dihydroxyandrost-1,
149
     4-dien-3-one);
150
                          Furazabol
                     (24)
     (17alpha-methyl-17beta-hydroxyandrostano[2,3-c]-furazan);
151
                          13beta-ethyl-17alpha-hydroxygon-4-en-3-one;
152
                     (25)
153
                     (26)
                          4-hydroxytestosterone
     (4,17beta-dihydroxyandrost-4-en-3-one);
154
155
                     (27)
                          4-hydroxy-19-nortestosterone
156
     (4,17beta-dihydroxy-estr-4-en-3-one);
157
                     (28) Mestanolone
158
     (17alpha-methyl-17beta-hydroxy-5-androstan-3-one);
159
                     (29) Mesterolone
160
     (1alpha-methyl-17beta-hydroxy-[5alpha]-androstan-3-one);
161
                     (30) Methandienone
     (17alpha-methyl-17beta-hydroxyandrost-1,4-dien-3-one);
162
163
                     (31)
                          Methandriol (17alpha-methyl-3beta,
164
     17beta-dihydroxyandrost-5-ene);
                       H. B. No. 1121
                                               ~ OFFICIAL ~
     25/HR43/R1778
```

PAGE 7 (RKM\KP)

```
165
                     (32)
                          Methasterone (2[alpha],
166
     17[alpha]-dimethyl-5[alpha]-androstan-17[beta]-ol-3-one;
167
                     (33)
                         Methenolone
168
     (1-methyl-17beta-hydroxy-5alpha-androst-1-en-3-one);
169
                     (34)
                           17alpha-methyl-3beta,
170
     17beta-dihydroxy-5a-androstane;
171
                           17alpha-methyl-3alpha,
                     (35)
     17beta-dihydroxy-5a-androstane;
172
173
                     (36)
                           17alpha-methyl-3beta,
174
     17beta-dihydroxyandrost-4-ene;
175
                     (37)
                           17alpha-methyl-4-hydroxynandrolone
176
     (17alpha-methyl-4-hydroxy-17beta-hydroxyestr-4-en-3-one);
177
                     (38) Methyldienolone
178
     (17alpha-methyl-17beta-hydroxyestra-4,9(10)-dien-3-one);
179
                     (39)
                          Methyltrienolone
180
     (17alpha-methyl-17beta-hydroxyestra-4,9-11-trien-3-one);
181
                     (40)
                          Methyltestosterone
182
     (17alpha-methyl-17beta-hydroxyandrost-4-en-3-one);
                          Mibolerone
183
                     (41)
184
     (7alpha, 17alpha-dimethyl-17beta-hydroxyestr-4-en-3-one);
185
                     (42) 17alpha-methyl-Deltal-dihydrotestosterone (17b
186
     beta-hydroxy-17alpha-methyl-5alpha-androst-1-en-3-one) (also known
     as 17-alpha-methyl-1-testosterone);
187
188
                     (43) Nandrolone (17beta-hydroxyestr-4-en-3-one);
```

```
189
                     (44)
                          19-nor-4-androstenediol
190
     (3beta, 17beta-dihydroxyestr-4-ene);
191
                     (45) 19-nor-4-androstenediol
192
     (3a, 17beta-dihydroxyestr-4-ene);
193
                     (46) 19-nor-5-androstenediol
194
     (3beta, 17beta-dihydroxyestr-5-ene);
195
                     (47) 19-nor-5-androstenediol
196
     (3alpha, 17beta-dihydroxyestr-5-ene);
197
                     (48)
                          19-nor-4,9(10)-androstadienedione
198
     (estra-4, 9(10) -diene3, 17-dione,
199
     19-norandrosta-4,9(10)-diene-3,17-dione);
200
                     (49) 19-nor-4-androstenedione
201
     (estr-4-en-3,17-dione);
202
                     (50) 19-nor-5-androstenedione
203
     (estr-5-en-3,17-dione);
204
                     (51) Norbolethone
205
     (13beta, 17alpha-diethyl-17beta-hydroxygon-4-en-3-one);
206
                     (52) Norclostebol
207
     (4-chloro-17beta-hydroxyestr-4-en-3-one);
208
                     (53) Norethandrolone
209
     (17alpha-ethyl-17beta-hydroxyestr-4-en-3-one);
210
                     (54) Normethandrolone
     (17alpha-methyl-17beta-hydroxyestr-4-en-3-one);
211
212
                     (55) Oxandrolone
213
     (17alpha-methyl-17beta-hydroxy-2-oxa-[5alpha]-androstan-3-one);
                       H. B. No. 1121
                                               ~ OFFICIAL ~
```

25/HR43/R1778 PAGE 9 (RKM\KP)

```
214
                     (56)
                          Oxymesterone
215
     (17alpha-methyl-4,17beta-dihydroxyandrost-4-en-3-one);
216
                     (57) Oxymetholone
217
     (17alpha-methyl-2-hydroxymethylene-17beta-hydroxy-[5alpha]-
218
     androstan-3-one);
219
                     (58)
                         Prostanozol
220
     (17[beta]-hydroxy-5[alpha]-androstano[3,2-c]pyrazole)
221
                     (59)
                          Stanozolol
222
     (17alpha-methyl-17beta-hydroxy-[5alpha]-androst-2-eno[3,2-c]-
223
     pyrazole);
224
                           Stenbolone
                     (60)
225
     (17beta-hydroxy-2-methyl-[5alpha]-androst-1-en-3-one);
226
                     (61) Testolactone
227
     (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid
228
     lactone);
229
                     (62)
                           Testosterone
230
     (17beta-hydroxyandrost-4-en-3-one);
231
                           Tetrahydrogestrinone
                     (63)
232
     (13beta, 17alpha-diethyl-17beta-hydroxygon-4, 9, 11-trien-3-one);
233
                     (64) Trenbolone
234
     (17beta-hydroxyestr-4,9,11-trien-3-one);
235
                     (65) Any salt, ester, or ether of a drug or
236
     substance described in this paragraph. Except such term does not
237
     include an anabolic steroid that is expressly intended for
238
     administration through implants to cattle or other nonhuman
```

H. B. No. 1121
25/HR43/R1778
PAGE 10 (RKM\KP)

~ OFFICIAL ~

330	annaina	and	+ h - +	hac	hoon	annround	htz	+ h o	Secretary	7 of	Uaal+h	and
439	Species	anu	tiiat	IIas	been	approved	DY	LIIE	secretar,		пеатии	anu

- 240 Human Services for such administration. If any person prescribes,
- 241 dispenses, or distributes such steroid for human use, the person
- 242 shall be considered to have prescribed, dispensed or distributed
- 243 an anabolic steroid within the meaning of this paragraph.
- 244 (q) Any material, compound, mixture or preparation
- 245 which contains any quantity of buprenorphine or its salts.
- 246 (h) Dronabinol (synthetic) in sesame oil and
- 247 encapsulated in a soft gelatin capsule in a United States Food and
- 248 Drug Administration approved drug product.
- (i) Any material, compound, mixture, or preparation
- 250 which contains any quantity of Tianeptine
- 251 (7-((3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]th
- 252 iazepin-11-yl)amino)heptanoic acid) or its salts, isomers, salts
- 253 of isomers, sulfate, free acid or derivative thereof.
- 254 (j) Any material, compound, mixture or preparation that
- 255 contains any quantity of kratom (mitragynine and
- 256 7-hydroxymytragynine) or its salts, isomers, salts of isomers,
- 257 sulfate, free acid or derivative thereof.
- 258 (B) Any material, compound, mixture or preparation which
- 259 contains any quantity of a Schedule III controlled substance other
- 260 than butalbital, and is listed as an exempt substance in 21 CFR,
- 261 Section 1308.22, 1308.24, 1308.26, 1308.32 or 1308.34, shall be
- 262 exempted from the provisions of the Uniform Controlled Substances
- 263 Law.

264 **SECTION 2.** This act shall take effect and be in force from 265 and after July 1, 2025.